About Teletype
Join
S
Sheetal
@sheetal
May 14, 2020

Ophthalmic Drugs Market Global Trends, Size, Opportunities and Forecast, 2020-2027

According to the Acumen Research and Consulting, the global Ophthalmic Drugs market is expected to reach at US$ 40 billion by 2026, along with the projected CAGR of 4.2 %from 2020-2026.

The published report global Ophthalmic Drugs market provides a holistic overview of the current market covering the current trends. The provided quantitative and qualitative data is based on the deeper analysis of the historical data and the current market situation that helps to provide an overview of the forecasted period.

Get Sample PDF @ https://www.acumenresearchandconsulting.com/request-sample/1323

The global Ophthalmic Drugs market report provides deeper insights on the factors driving the global market along with the factors that are responsible to hamper the growth. In addition, the report provides the opportunities in the global Ophthalmic Drugs market that would help the competitors to increase the profit share.

The global Ophthalmic Drugs market report provides the quantitative information of the target segment that is covered in the report along with the regional data comparison.

The report provides an overview value chain analysis, Porters Five analysis, and cost structure analysis gives an idea of the industrial outlook. The global Ophthalmic Drugs market report covers the data of the major geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the report also covers the country cross section providing deeper insights of the particular region.

The published global Ophthalmic Drugs market report provides information about the major players operating in the target market. The company profile section provides important information about the major players, along with the financial overview, product segment revenue, the geographical presence of the company. It also provides information related to business development activities by the players such as merger & acquisition, partnerships and agreements.

The global Ophthalmic Drugs market report also covers the products information that is offered by the particular players along with the specification. In addition, the player positioning based on their business strengths and product offerings which provides the competitive outlook of the industry.

Market participants

ALLERGAN PLC ; Pfizer, Inc. ; Santen Pharmaceutical Co., Ltd. ; Johnson & Jean – Services, Inc. ; Merck Sharp & Dohme Corp. ; and Genentech, Inc. AG ; Bausch & Lomb, Inc. ; Regeneron Pharmaceutical, Inc., among others.

Market segmentation

By Drug Class Outlook

  • Antiallergy
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Agents
  • Anti-inflammatory
    • Nonsteroidal Drugs
    • Steroidal Drugs
  • Antiglaucoma
  • Others

By Disease Outlook

  • Dry Eye
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye Drops
    • Ointments
  • Allergies
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Glaucoma
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Inflammation/Infection
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Retinal Disorders
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Uveitis
    • Gels
    • Eye Solutions
    • Capsules & Tablets
    • Eye drops
    • Ointments
  • Others

By Dosage Form

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

By Product Type

  • Prescription Drugs
  • OTC Drugs

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Table of content

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Ophthalmic Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Ophthalmic Drugs Market By Drug Class Outlook
1.2.2.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Drug Class Outlook (2015-2026)
1.2.2.2. Global Ophthalmic Drugs Market Revenue Share By Drug Class Outlook in 2017
1.2.2.3. Antiallergy
1.2.2.4. Anti-Vascular Endothelial Growth Factor (Anti-Vegf) Agents
1.2.2.5. Anti-inflammatory
1.2.2.5.1. Nonsteroidal Drugs
1.2.2.5.2. Steroidal Drugs
1.2.2.6. Antiglaucoma
1.2.2.7. Others
1.2.3. Ophthalmic Drugs Market By Disease Outlook
1.2.3.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Disease Outlook (2015-2026)
1.2.3.2. Global Ophthalmic Drugs Market Revenue Share By Disease Outlook in 2017
1.2.3.3. Dry Eye
1.2.3.4. Allergies
1.2.3.5. Glaucoma
1.2.3.6. Inflammation/Infection
1.2.3.7. Retinal Disorders
1.2.3.8. Uveitis
1.2.3.9. Others
1.2.4. Ophthalmic Drugs Market By Dosage Form
1.2.4.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Dosage Form (2015-2026)
1.2.4.2. Global Ophthalmic Drugs Market Revenue Share By Dosage Form in 2017
1.2.4.3. Gels
1.2.4.4. Eye Solutions
1.2.4.5. Capsules & Tablets
1.2.4.6. Eye Drops
1.2.4.7. Ointments
1.2.4.8. Others
1.2.5. Ophthalmic Drugs Market By Product Type
1.2.5.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison By Product Type (2015-2026)
1.2.5.2. Global Ophthalmic Drugs Market Revenue Share By Product Type in 2017
1.2.5.3. Prescription Drugs
1.2.5.4. OTC Drugs
1.2.5.5. Others
1.2.6. Ophthalmic Drugs Market by Geography
1.2.6.1. Global Ophthalmic Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Ophthalmic Drugs Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Ophthalmic Drugs Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Ophthalmic Drugs Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Ophthalmic Drugs Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Ophthalmic Drugs Major Manufacturers in 2017

CHAPTER 4. Ophthalmic Drugs Market By Drug Class Outlook

4.1. Global Ophthalmic Drugs Revenue By Drug Class Outlook
4.2. Antiallergy
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Anti-Vascular Endothelial Growth Factor (Anti-Vegf) Agents
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Anti-inflammatory
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4.3. Nonsteroidal Drugs
4.4.4. Steroidal Drugs
4.5. Antiglaucoma
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. Ophthalmic Drugs Market By Disease Outlook

5.1. Global Ophthalmic Drugs Revenue By Disease Outlook
5.2. Dry Eye
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Allergies
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Glaucoma
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Inflammation/Infection
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.6. Retinal Disorders
5.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.7. Uveitis
5.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.8. Others
5.8.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.8.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. Ophthalmic Drugs Market By Dosage Form

6.1. Global Ophthalmic Drugs Revenue By Dosage Form
6.2. Gels
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Eye Solutions
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Capsules & Tablets
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Eye Drops
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.6. Ointments
6.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.7. Others
6.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 7. Ophthalmic Drugs Market By Product Type

7.1. Global Ophthalmic Drugs Revenue By Product Type
7.2. Prescription Drugs
7.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.3. OTC Drugs
7.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 8. North America Ophthalmic Drugs Market By Country

8.1. North America Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. North America Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Ophthalmic Drugs Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 9. Europe Ophthalmic Drugs Market By Country

9.1. Europe Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Europe Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 10. Asia-Pacific Ophthalmic Drugs Market By Country

10.1. Asia-Pacific Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Asia-Pacific Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 11. Latin America Ophthalmic Drugs Market By Country

11.1. Latin America Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Latin America Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 12. Middle East Ophthalmic Drugs Market By Country

12.1. Middle East Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Middle East Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 13. Africa Ophthalmic Drugs Market By Country

13.1. Africa Ophthalmic Drugs Market Revenue and Growth Rate, 2015 – 2026 ($Million)
13.2. Africa Ophthalmic Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Drug Class Outlook, 2015 – 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 – 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Allergan Plc
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Pfizer, Inc.
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Santen Pharmaceutical Co., Ltd.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. Johnson & Jean – Services, Inc.
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Merck Sharp & Dohme Corp.
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Genentech, Inc. AG
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Bausch & Lomb, Inc.
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Regeneron Pharmaceutical, Inc.
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. Others
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

Buy this premium report @ https://www.acumenresearchandconsulting.com/buy-now/0/1323

Contact us:

Sheetal k

Email: [email protected]

Phone: +14079154157 | +14089009135

Website: https://www.acumenresearchandconsulting.com

Acumen Research and Consulting (ARC)
May 14, 2020, 07:29
0 reactions
0 views